Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080421 | 0.95 | POLB (0.91) | POLBEPHX1EPHX2GABRPGABRD | |
| Hydrochloric Acid SCHEMBL30473852 | 0.93 | POLB (0.88) | POLBEPHX1EPHX2GABRPGABRD | |
| SCHEMBL9349114 | 0.92 | POLB (0.85) | POLBEPHX1EPHX2GABRPGABRD | |
| SCHEMBL4701164 | 0.91 | POLB (0.84) | POLBEPHX1EPHX2TSHRL3MBTL1 | |
| SCHEMBL2016778 | 0.91 | POLB (0.83) | POLBEPHX1EPHX2GABRPGABRD | |
| SCHEMBL24323730 | 0.90 | POLB (0.81) | POLBEPHX1EPHX2TSHRL3MBTL1 | |
| SCHEMBL6378905 | 0.90 | POLB (0.81) | POLBEPHX1EPHX2TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL26133008 | 0.90 | POLB (0.81) | POLBEPHX1EPHX2TSHRGNAI3 | |
| Hydrochloric Acid SCHEMBL1999078 | 0.89 | POLB (0.80) | POLBEPHX1EPHX2GABRPGABRD | |
| SCHEMBL12820424 | 0.89 | POLB (0.79) | POLBEPHX1EPHX2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-11377453-B2 | Crystal of compound having JAK-inhibiting activity | NIPPON SHINYAKU CO., LTD. (JP) | 2022-07-05 | — | — | US | disclosed |
| CN-108699082-B | Crystals of a compound having a JAK inhibitory effect | 日本新药株式会社 | 2021-04-09 | — | — | CN | disclosed |
| US-20210017191-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | NIPPON SHINYAKU CO., LTD. (JP) | 2021-01-21 | — | — | US | disclosed |
| EP-3424930-B1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | NIPPON SHINYAKU CO LTD (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10822350-B2 | Crystal of compound having JAK-inhibiting activity | NIPPON SHINYAKU CO., LTD. (JP) | 2020-11-03 | — | — | US | disclosed |
| EP-3190116-B1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-107108653-B | Pyrazolothiazole compound and medicine | 日本新药株式会社 | 2019-04-09 | — | — | CN | disclosed |
| US-20190048023-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | NIPPON SHINYAKU CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| EP-3424930-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | Nippon Shinyaku Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2383259-A1 | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008022979-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | POLB 2022/4885EPHX1 3716/4885EPHX2 4064/4885 |
| US-11377453-B2 | Crystal of compound having JAK-inhibiting activity | JAK1, JAK2, JAK3 | POLB 2747/4885EPHX1 3298/4885EPHX2 3674/4885 |
| US-10822350-B2 | Crystal of compound having JAK-inhibiting activity | JAK1, JAK2, JAK3 | POLB 2747/4885EPHX1 3298/4885EPHX2 3674/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | POLB 3825/4885EPHX1 3179/4885EPHX2 2217/4885 |
| US-20210017191-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | JAK1, JAK2, JAK3 | POLB 2747/4885EPHX1 3298/4885EPHX2 3674/4885 |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | POLB 1263/4885EPHX1 2300/4885EPHX2 2065/4885 |
| US-20190048023-A1 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY | JAK1, JAK2, JAK3 | POLB 2747/4885EPHX1 3298/4885EPHX2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.